13 octubre 2015
Failure to eliminate bias can skew what we think we know about a drug, waste time and money on trials that prove ‘futile’ and drive up the price of medications. Only 5 percent of agents that show anticancer activity in preclinical development are eventually licensed while in cardiovascular disease, for example, the rate is 20 percent, say experts.
http://www.sciencedaily.com/releases/2015/10/151013155430.htm
